RevolutionLogo.png
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
September 08, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
August 10, 2020 07:30 ET | Revolution Medicines, Inc.
Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors Targeted Combination Strategy Underpins Initiation of New Clinical...
RevolutionLogo.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 13, 2020 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
RevolutionLogo.png
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 08, 2020 22:48 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock...
RevolutionLogo.png
Revolution Medicines Announces Proposed Public Offering of Common Stock
July 06, 2020 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common...
RevolutionLogo.png
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
June 30, 2020 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif. and BOSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
June 22, 2020 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
June 22, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
June 18, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
June 09, 2020 07:30 ET | Revolution Medicines, Inc.
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) --...